Dako enters into collaboration with Genentech on the regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for pertuzumab
(Thomson Reuters ONE) -
Dako, a worldwide provider of cancer diagnostics solutions, has signed an
agreement with Genentech, a member of the Roche Group, to collaborate on the
regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as
companion diagnostics for a Genentech investigational drug candidate,
pertuzumab, in patients with advanced HER2-positive breast cancer.
Under the terms of the agreement, Dako and Genentech will collaborate on the
regulatory submissions for HercepTest(TM) and HER2 FISH pharmDx(TM) in the US
market to identify cancer patients who may be eligible for pertuzumab.
"We're pleased to provide Genentech access to our leading competencies. I
strongly believe collaborating with Genentech on the joint FDA approval for
companion diagnostics for pertuzumab will benefit many breast cancer patients in
the future," says Lars Holmkvist, CEO of Dako.
The collaboration on the joint submission process for HercepTest(TM) and HER2
FISH pharmDx(TM) as companion diagnostics for pertuzumab is in line with Dako's
ongoing strategy to combine its strengths with pharmaceutical companies to grow
the offering of Dako's companion diagnostic assays.
Media Contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and operating in more than 70 countries, Dako covers essentially all
of the global anatomic pathology markets. Dako is owned by a private equity fund
EQT.www.dako.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1570302]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Rubicon Provides Drilling and Operational Update F2 Gold System, Phoenix Gold Project, Red Lake, Ontario
Datum: 09.12.2011 - 16:00 Uhr
Sprache: Deutsch
News-ID 95620
Anzahl Zeichen: 2534
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako enters into collaboration with Genentech on the regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for pertuzumab"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
